• linkedin
  • Increase Font
  • Sharebar

    PCa-specific mortality not affected by comorbidity

    Increased comorbidity does not raise death risk regardless of radical treatment type


    Watchful waiting, ADT groups analyzed

    A subsequent subset analysis for each treatment group found that among men in the watchful-waiting group, prostate cancer-specific mortality was associated with any comorbidity (Charlson index scores 1, 2, or 3+) versus no comorbidity (Charlson index score 0). However, this association disappeared when statistically adjusted for patient and tumor characteristics. A subgroup analysis of data for patients in the androgen deprivation therapy group found that a Charlson comorbidity index of ≥3 was associated with a modest 1.10 hazard ratio for prostate cancer-specific mortality compared to patients without comorbidities, both before and after adjusting for patient and tumor characteristics (p=.004 and .014, respectively).

    Read: Top 9 peer-reviewed prostate cancer papers of 2017

    It is possible that cause of death misclassifications in the Swedish deaths registry, difficulty detecting relevant comorbid conditions, or early deaths from non-cancer causes might have affected the findings, the authors acknowledged.

    More from Urology Times:

    Study: Active surveillance uptake remains low

    Tissue-based PCa assays not robust to multifocality

    CCP score further risk stratifies surveillance candidates

    Subscribe to Urology Times to get monthly news from the leading news source for urologists.


    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available